In addition, we monitored the proportion of CD20+ T-cells from the time of the diagnosis of MM, and through the follow-up of treatment and looked for a correlation between the CD20+ T-cells ratios and the proportion of measurable residual disease (MRD) of MM samples. Here, MS4A1 is linked to Miyoshi myopathy.